{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Number of Subjects to be Enrolled / Randomized:', 'Approximately 600 subjects', 'Study Design Overview:', 'This is a global, open-label, randomized Phase 3 study in adult subjects with locally advanced or', 'metastatic urothelial cancer who have received a platinum-containing chemotherapy and have', 'experienced disease progression or relapse during or following treatment with an immune', 'checkpoint inhibitor. Approximately 600 subjects will be randomized to EV (Arm A) or', 'chemotherapy (Arm I B) in a 1:1 ratio. Subjects will be stratified according to the following:', 'Eastern Cooperative Oncology Group Performance Status (ECOG PS), regions of the world and', 'liver metastasis.', 'os is the primary endpoint. OS is defined as the time from randomization to the date of death.', 'Secondary endpoints include PFS1, ORR, DOR, DCR, safety and QOL/PRO.', 'Subjects in Arm A will receive EV on Days 1, 8 and 15 of each 28-day cycle. Subjects in arm B', 'will receive docetaxel, paclitaxel or vinflunine (as decided by the investigator prior to', 'randomization: vinflunine is a choice of comparator only in countries where it is approved for', 'urothelial cancer) on Day 1 of every 21-day cycle. Within the control arm, the overall proportion', 'of subjects receiving vinflunine will be capped at approximately 35%. Subjects will continue to', 'receive study treatment until radiological disease progression as determined per investigator', 'assessment or other discontinuation criteria are met or upon study termination, or study', 'completion, whichever occurs first. No on-study crossover will be allowed other than as allowed', 'in [Appendix 12.10 This study will consist of 3 phases: screening, treatment and follow-up.', 'Screening will take place up to 28 days prior to randomization. Subjects will start with cycle 1', 'and continue on to subsequent 21-day or 28-day cycles until one of the discontinuation criteria are', 'met. A treatment cycle is defined as 28 days for Arm A and 21 days for Arm B. Subjects', 'randomized to Arm A (EV) will receive treatment and evaluation on Days 1, 8 and 15 of all', 'treatment cycles. Subjects randomized to Arm B (docetaxel, paclitaxel or vinflunine) will receive', 'treatment and evaluation on Day 1 of all treatment cycles.', 'Subjects will be evaluated for response according to the RECIST V1.1. Imaging for both arms', 'will be performed at baseline and every 56 days ( 7 days) from the first dose of study treatment', 'throughout the study until PFS1 is documented by radiological disease progression or the subject', 'is lost to follow-up, death, withdraws study consent or starts a subsequent anti-cancer therapy.', 'Baseline imaging performed prior to informed consent as standard of care may be used so long as', 'it is performed within 28 days prior to randomization. All subjects will have a bone scan', '(scintigraphy) performed at screening/baseline. Subjects with positive bone scans at baseline will', 'have a bone scan performed every 56 days ( 7 days) throughout the study or more frequently if', 'clinically indicated. Subjects should have a follow-up bone scan performed if clinically indicated', 'regardless of baseline status. Brain scans (computed tomography with contrast/magnetic', 'resonance imaging [MRI]) will only be performed if clinically indicated at screening/baseline and', 'repeated as clinically indicated or per standard of care throughout the study.', 'QOL assessments and PRO will be collected at protocol-specified time points from all', 'randomized subjects. The following validated tools will be used: European Organisation for', 'Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) and', 'EuroQOL 5-dimensions (EQ-5D-5L). Healthcare Resource Utilization (HRU) information will be', 'collected at protocol-specified time points with particular focus on the number of subjects who', 'have an unplanned use of healthcare resources related to clinical or AEs from subjects assigned to', 'treatment arms A and B.', '14 Sep 2020', 'Astellas', 'Page 18 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Blood samples for pharmacokinetics and ATA will be collected throughout the study for subjects', 'randomized into Arm A. Validated assays will be used to measure the concentrations of EV ADC', 'and MMAE in serum or plasma and to assess ATA. Pharmacokinetic samples will not be collected', 'from subjects randomized into Arm B. Samples for exploratory biomarkers will be collected at', 'protocol-specified time points. Biomarker assessments will not be used for subject selection.', 'Following discontinuation from study drug, subjects will have a follow-up visit 30 days (+ 7 days)', 'after their last dose of drug for safety assessments. If a subject discontinues study drug prior to', 'radiographic disease progression (i.e., PFS1), the subject should enter the post treatment follow-up', 'period and continue to undergo imaging assessments every 56 days ( 7 days) until PFS1 is', 'documented or the subject starts another anticancer treatment, whichever occurs earlier.', 'Following PFS1, subjects will enter the long-term follow-up period and be followed per', 'institutional guidelines, but not less than every 3 months from the date of the follow-up visit for', 'survival status and progression status on subsequent therapy (i.e., PFS2).', 'Subjects will be followed until PFS2 is documented or the subject starts another anticancer', 'treatment, whichever occurs earlier. All subsequent anticancer therapy including date and site of', 'progression for PFS2 will be recorded on the case report form.', 'Following PFS2, subjects will enter the survival follow-up period and be followed every 3 months', 'for survival status until death, lost to follow-up, withdrawal of study consent, or study termination', 'by sponsor. This study is expected to end once final survival analysis is complete.', 'An Independent Data Monitoring Committee (IDMC) will be chartered to oversee safety and the', 'planned interim efficacy analysis, which will occur after at least 285 OS events (about 65% of the', 'total planned events) are observed. The primary analysis will occur at 439 OS events. The IDMC', 'may recommend to the sponsor whether the trial should be terminated, modified or continue', 'unchanged based on ongoing reviews of safety data and interim efficacy analysis. Further details', 'will be outlined in the IDMC charter.', 'Inclusion/Exclusion Criteria:', 'Inclusion:', 'Subject is eligible for the study if all of the following apply:', '1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written', 'informed consent and privacy language as per national regulations (e.g., Health Insurance', 'Portability and Accountability Act [HIPAA] Authorization for US sites) must be obtained from', 'the subject prior to any study-related procedures (including withdrawal of prohibited', 'medication, if applicable).', '2. Subject is legally an adult according to local regulation at the time of signing informed', 'consent.', '3. Subject has histologically or cytologically confirmed urothelial carcinoma (i.e., cancer of the', 'bladder, renal pelvis, ureter or urethra). Subjects with urothelial carcinoma (transitional cell)', 'with squamous differentiation or mixed cell types are eligible.', '4. Subject must have experienced radiographic progression or relapse during or after a CPI (anti-', 'programmed cell death-1 [PD-1] or anti-programmed cell death-ligand 1 [PD-L1]) for locally', 'advanced or metastatic disease. Subjects who discontinued CPI treatment due to toxicity are', 'eligible provided that they have evidence of disease progression following discontinuation. The', 'CPI need not be the most recent therapy. Subjects for whom the most recent therapy has been a', 'non-CPI based regimen are eligible if they have progressed/relapsed during or after their most', 'recent therapy. Locally advanced disease must not be amenable to resection with curative', 'intent per the treating physician.', '14 Sep 2020', 'Astellas', 'Page 19 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}